아피셀테라퓨틱스

팝업레이어 알림

Bridging
from Science
to Medicine;

Cutting-edge Technologies and Platforms Integration
for a Balanced Immune System

Revolutionizing
Immunotherapies

Novel Class of Biotherapeutics + Advanced MSCs Technologies
= New Horizon for Human Cell & Gene Therapy

1 /

AffyXell Therapeutics Co., Ltd.

AffyXell Therapeutics Co., Ltd is a cell & gene therapy development company founded in January 23rd, 2020 as a joint venture by Daewoong Pharmaceuticals and Avacta Life Science, U.K. AffyXell is developing the next-generation cell & gene therapeutics (AFX platform technology)
which is reinforced for immunomodulation.

The AFX platform technology is based on Daewoong’s mesenchymal stem cell platform (DW-MSC) that has overcome current limitation of tissue-derived mesenchymal stem cell, and Affimer platform technology has been adapted to improve immunomodulation.

About the technology

New Connection
: Restoring Immune Balance

AffyXell Therapeutics Co., Ltd. is developing a novel cell & gene therapy based
on mesenchymal stem cell (MSC) to obstacle the diseases that come from imbalance
of immune system homeostasis.
Immunomodulation function by MSC is further increased with Affimer® platform,
restoring immunologic balance, and we will do the best we can to lead treating diseases
with new therapeutic approach that can resolve fundamental causes of intractable
diseases like immune rejection and autoimmune diseases.

Platform Technology